Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

Home › Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT.

16.11	UK Pizza Hut to raise funds after Budget tax hikes
16.11	Record numbers seek help with water bills
16.11	Billions at stake in court battle over North Sea oil
15.11	China megaport opens up Latin America as wary US looks on
15.11	China megaport opens up Latin America as wary US looks on
15.11	Post Office scandal: Who knew what and when?
15.11	Mortgage costs rise despite interest rate cut
15.11	Health stocks hit after Trump taps RFK Jr for top job
Consumer Goods and Services »

je.st